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Background/Aims: Myelodysplastic syndrome (MDS) is caused by genetic and 
epigenetic alteration of hematopoietic precursors and immune dysregulation. 
Approximately 20% of patients with MDS develop an autoimmune disease (AID). 
Here, we investigated whether particular genetic mutations are associated with 
AID in patients with MDS. 
Methods: Eighty-eight genetic mutations associated with myeloid malignancy 
were sequenced in 73 MDS patients. The association between these mutations and 
AID was then analyzed. 
Results: The median age of the 73 MDS patients was 70 years (interquartile range, 
56 to 75), and 49 (67.1%) were male. AID was observed in 16 of 73 patients (21.9%). 
Mutations were detected in 57 (78.1%) patients. The percentage (68.8% vs. 80.7%, p 
= 0.32) and the mean number of mutations (1.8 ± 1.6 vs. 2.2 ± 1.8, p = 0.34) in MDS 
patients with or without AID were similar. However, the ten-eleven transloca-
tion-2 (TET2) mutation rate was significantly higher in patients with AID than 
in those without (31.3% vs. 5.3%, respectively; p = 0.001). All TET2 mutations were 
variants of strong clinical significance. 
Conclusions: Mutation of TET2 in patients with MDS may be associated with in-
creased risk of developing AID. 
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INTRODUCTION
Myelodysplastic syndrome (MDS) is a heterogeneous 
group of clonal hematologic diseases characterized by 
ineffective hematopoiesis in the bone marrow (BM) and 
peripheral cytopenia, with the potential to progress to 
acute myeloid leukemia or fatal BM failure [1]. A key 
pathophysiologic process in MDS is accumulation of 
genetic damage. Mutation of genes that regulate critical 
cellular functions can drive malignant transformation 
[2]. The resulting unopposed activation and prolifera-
tion of immune cells might ultimately disrupt normal 
immune responses in MDS patients and contribute to 
development of autoimmune disease (AID). Indeed, ap-
proximately 20% of MDS patients develop AIDs [3], sug-
gesting that MDS-associated AIDs might result from 
similar genetic changes. 
Previously, we demonstrated that certain AIDs in 
MDS patients are associated with distinctive karyotypic 
abnormalities and outcomes [4]. While a karyotypic ab-
normality indicates a radical change in gene dose (with 
duplication or deletion of large gene segments), genetic 
modification without karyotypic abnormality can still 
drive development of MDS. Mutation of these “ma-
lignancy-associated genes” contributes to AIDs. One 
critical mutation may involve proteins that regulate 
epigenetic modifications, which in turn impact cellular 
function. For example, mutation of ten-eleven translo-
cation 2 (TET-2) is associated with both MDS and exac-
erbated inflammatory responses [5]. 
Here, we investigated whether particular gene mu-
tations frequently associated with myeloid malignancy 




A total of 250 patients initially diagnosed with MDS at 
Seoul National University Hospital from January 2000 
to December 2014 were included. Exclusion criteria 
were as follows: age at the time of diagnosis < 18 years, 
initial diagnosis of aplastic anemia or leukemia, and 
therapy-related MDS. Patients who developed an AID 
more than 5 years before MDS diagnosis were exclud-
ed. Patients from whom adequate amounts of DNA (i.e., 
≥ 800 ng) could not be extracted were also excluded. A 
final cohort of 73 treatment-naive patients was included 
in the analysis (Fig. 1). Laboratory and clinical data were 
obtained at time of BM sampling for gene sequencing. 
MDS subtypes were defined according to the World 
Health Organization classification [6]. The study was 
approved by the Institutional Review Board of Seoul Na-
tional University Hospital and conducted in accordance 
with the Declaration of Helsinki (IRB protocol number: 
1604-082-754). Written informed consent was obtained 
from all patients. 
Definition of AID
Medical records were reviewed to evaluate the presence 
of an AID. Diagnosis of an AID was based on the 2010 
American College of Rheumatology/Annual European 
Congress of Rheumatology criteria for rheumatoid ar-
thritis (RA) [7], the 1984 modified New York criteria for 
ankylosing spondylitis [8], and the Bohan and Peter [9] 
criteria for idiopathic inflammatory myopathies. Auto-
immune thyroiditis was defined as abnormal thyroid 
function in the presence of anti-thyroid antibodies (i.e., 
anti-thyroid peroxidase antibodies and anti-thyroid 
stimulating hormone receptor antibodies). Immune 
thrombocytopenia (ITP) was defined as thrombocytope-
nia in the presence of antiplatelet antibodies after ex-
cluding other causes of thrombocytopenia. Hemolytic 
anemia (HA) was defined as anemia in the presence of 
a positive direct Coombs test and laboratory evidence 
of hemolysis (such as increased lactate dehydrogenase 
Exclusion criteria
•  < 18 years old
•  Inadequate amount of isolated DNA 
 contents (i.e., gDNA < 800 ng) 
•  Initially diagnosed with aplastic anemia 
 or leukemia
•  Therapy-related MDS patients
•  Patients who developed an autoimmune 






250 Patients diagnosed with 
MDS at SNUH
between 2000 and 2014
73 MDS patients underwent
sequencing
Figure 1. Flow chart of study patients. MDS, myelodysplas-
tic syndrome; SNUH, Seoul National University Hospital; 
gDNA, genomic DNA; AID, autoimmune disease. 
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levels and decreased haptoglobin levels). Panniculitis, 
Sweet syndrome, psoriasis, and uveitis were diagnosed 
clinically by consulting dermatologists and ophthal-
mologists, respectively. 
BM histology
Wright-stained BM smears and hematoxylin and eo-
sin-stained sections of BM trephine biopsies were re-
viewed by hematopathologists. 
Targeted sequencing of 88 MDS-associated genes
Eighty-eight genes associated with myeloid malignancy 
were selected for targeted sequencing (Supplementa-
ry Table 1) [10]. To construct a sequencing library, ge-
nomic DNA (gDNA) was extracted from BM cells using 
the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, 
CA, USA). A total target length of 259 Kb regions, with 
paired-ends of 150 bp, was sequenced on an Illumina 
HiSeq 2500 platform (Illumina, San Diego, CA, USA) us-
ing the rapid-run sequencing mode. The mean time be-
tween MDS diagnosis and gene sequencing was 4.4 days.
Processing of sequencing data and variant calling 
A schematic diagram illustrating the data processing 
pipeline and the algorithm used for variant calling of so-
matic mutations is shown in Supplementary Fig. 1. The 
raw data were mapped to the reference genome (hg19) 
using the Burrows-Wheeler Aligner (BWA, v0.62). Du-
plicate PCR reads were removed using Picard 1.98, and 
variants were called using “UnifiedGenotyper” in GATK 
2.7-2. Variants flagged as “LowQual” and low depth (< 
10) were excluded. Variants were annotated using AN-
NOVAR and candidate gene mutations were selected 
according to the criteria described in the Supplemen-
tary Table 1. All synonymous variants were discarded. 
Missense single nucleotide variants (SNVs) reported in 
public databases, including single nucleotide polymor-
phism database (dbSNP), ESP6500, and the 1,000 ge-
nomes project, with a frequency of > 0.5% were filtered 
as polymorphisms. In addition, an in-house database of 
Korean polymorphisms, derived from the sequence data 
of 273 normal Koreans, was used as a private database 
to filter polymorphisms. SNVs that were found in more 
than two persons in the Korean database (allele fraction 
≥ 0.2%) were filtered out. From the filtered SNVs with 
low depth, SNV variants known from previous MDS 
studies to be hotspot mutations were rescued [11,12] us-
ing the criterion of > 5 total reads with supporting reads. 
Mapping errors were confirmed by visual inspection us-
ing the IGV browser. Among missense SNVs not report-
ed previously, SNV mutations predicted to be benign by 
SIFT and Polyphen software were removed.
Statistical analysis
Continuous variables were expressed as the mean ± stan-
dard deviation or median (interquartile range [IQR]), 
and categorical variables were expressed as a number 
(%). Student’s t test and the chi-square test were used 
to compare continuous or categorical variables between 
the two groups. A p values ≤ 0.05 were considered statis-
tically significant. All statistical analyses were performed 
using SPSS version 23.0 (IBM Co., Armonk, NY, USA).
RESULTS
Baseline characteristics of MDS patients with or 
without AID
The median age of the 73 MDS patients was 70 years 
(IQR, 56 to 75), and 49 patients (67.1%) were male. The 
median follow-up duration after MDS diagnosis was 1.8 
years (IQR, 0.9 to 3.3). Among the 73 patients, 16 (21.9%) 
were diagnosed with an AID: four (25%) with autoim-
mune thyroiditis, three (18.8%) with immune thrombo-
cytopenia, two (12.5%) with HA, one (6.3%) with RA, one 
(6.3%) with panniculitis, and one (6.3%) with idiopathic 
Autoimmune hemolytic anemia (n = 2)
Idiopathic thrombocytopenic purpura (n = 3)
Autoimmune thyroiditis (n = 4)
Psoriasis (n = 1)
Inflammatory myopathy (n = 1)
Sweet syndrome (n = 1)
Rheumatoid arthritis (n = 1)
MDS diagnosis
Panniculitis (n = 1)
Ankylosing spondylitis (n = 1)
–5 –4 –3 –2 –1 0 1 2 3 4 5 6 7 8 9 10 yr
Uveitis (n = 1)
Figure 2 . Temporal association between autoimmune 
disease and myelodysplastic syndrome (MDS) diagnosis. 
Among the 73 patients, 16 (21.9%) were diagnosed with an 
AID: four (25%) autoimmune thyroiditis, three (18.8%) im-
mune thrombocytopenia, two (12.5%) hemolytic anemia, 
one (6.3%) RA, one (6.3%) panniculitis, one (6.3%) idiopathic 
inflammatory myopathy.
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inflammatory myopathy (Fig. 2). The baseline character-
istics of MDS patients with or without an AID are shown 
in Table 1. The two groups did not differ in terms of sex, 
age, MDS subtype, and laboratory parameters.
The median time between diagnosis of MDS and AID 
was 0.03 years (IQR, –0.8 to 1.0). Most AIDs were diag-
nosed shortly before or after MDS diagnosis. One pa-
tient developed uveitis 9 years after MDS diagnosis, and 
two patients (one RA and one autoimmune thyroiditis) 
developed AID 2 years after MDS diagnosis. The AIDs 
were treated with corticosteroid with or without im-
mune suppressants. The case of autoimmune thyroid-
itis was treated with methimazole. All patients improved 
after treatment.
TET2 mutation is associated with increased risk of 
autoimmunity in MDS patients
The 88 selected genes sequenced herein are listed in 
Supplementary Table 1. Fifty-seven of 73 MDS patients 
(78.1%) harbored a genetic mutation in at least one of 
the selected genes. The presence of a mutation (68.8% 
vs. 80.7%, p = 0.32) and the mean number of mutations 
(1.8 ± 1.6 vs. 2.2 ± 1.8, p = 0.34) did not differ between the 
AID and non-AID groups. Strikingly, the rate of TET2 
Table 1. Baseline characteristics in MDS patients with AID or without AID
Characteristic AID (n = 16) No AID (n = 57) p value
Age at MDS diagnosis, yr 66.5 (56.3–72.5) 70 (56–75) 0.66
Female sex 7 (43.7) 17 (29.8) 0.37
Follow-up duration, yr 2.1 (0.9–4.1) 1.8 (0.9–2.9)
Autoimmune disease NA
Hemolytic anemia 2 (12.5)
ITP 3 (18.8)
Autoimmune thyroiditis 4 (25.1)
Rheumatoid arthritis 1 (6.3)
Ankylosing spondylitis 1 (6.3)
Panniculitis 1 (6.3)
Sweet syndrome 1 (6.3)
Uveitis 1 (6.3)
Psoriasis 1 (6.3)
Inflammatory myositis 1 (6.3)
MDS, subtypes 0.43
RCUD 3 (18.8) 12 (21.1)
RCMD 5 (31.2) 10 (17.5)
RAEB 4 (25.0) 24 (42.1)
Othersa 4 (25.0) 11 (19.3)
Karyotypic abnormality 6 (37.5) 24 (42.1) 0.99
Platelet (× 103/µL) 126.3 ± 127.1 115.0 ± 148.0 0.57
Absolute neutrophil count, /µL 1,295 ± 1,129 1,464 ± 1,735 0.65
Absolute lymphocyte count, /µL 1,180 ± 860.9 1,021.0 ± 579.1 0.49
ANA positivity 1/16 (6.3) 10/56 (17.6) 0.82
Values are presented as median (interquartile range), number (%), or mean ± SD. 
MDS, myelodysplastic syndrome; AID, autoimmune disease; ITP, immune thrombocytopenia; NA, non-applicable; RCUD, 
refractory cytopenia with unilineage dysplasia; RCMD, refractory cytopenia with multilineage dysplasia; RAEB, refractory 
anemia with excess blasts; ANA, anti-nuclear antibody.
aOthers include refractory anemia with ringed sideroblasts and MDS-unclassifiable.
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mutation was significantly higher in MDS patients with 
an AID than in those without (31.3% [n = 5/16] vs. 5.3% [n 
= 3/57], respectively; p = 0.001). The patients with TET2 
mutation were older than those without (75 [70.8–84] vs. 
68 [55.5–73], p = 0.02). However, the median age did not 
differ between the AID and non-AID patients (66.5 years 
[56.3–72.5] vs. 70 years [56–75], p = 0.66) (Table 1).
Logistic regression analysis revealed that TET2 muta-
tion was associated significantly with an increased risk 
of AID (odds ratio [OR], 8.18; 95% confidence interval 
[CI], 1.70 to 39.38; p = 0.009) (Table 2). All observed TET2 
mutations were variants of strong clinical significance, 
including stop-gain and frameshift deletion and inser-
tion mutations (Table 3).
DISCUSSION
To the best of our knowledge, this study is the first to 
examine the potential effects of mutations in 88 selected 
myeloid malignancy-associated genes on development 
of AID in patients with MDS. Mutation of TET2, an epi-
genetic regulator, was the single most significant factor 
that increased the AID risk in MDS patients.
The prevalence of AID in the general population is 
about 3% to 5%, whereas that in MDS patients ranges 
from 10% to 30% [13-15]. Consistent with this, 16 (21.9%) 
of the patients with MDS in the present study developed 
an AID. This tight association between MDS and AID in-
dicates that they may share common pathophysiologic 
mechanisms, including genetic and/or epigenetic mod-
ifications. We and others reported that particular karyo-
typic abnormalities are associated with specific AIDs in 
patients with MDS. For example, trisomy 8 is associated 
with Behçet disease in MDS patients [4,16], whereas del 
(5q) is common in MDS patients with RA [17]. However, 
karyotypic abnormalities represent a substantial quan-
titative alteration in whole genome material, and 40.3% 
of MDS patients without an abnormal karyotype still de-
velop an AID [4]. Here, we focused on the association be-
tween AID and gene mutations that are critical for devel-
opment of hematologic malignancy [18]. As expected, 57 
of 73 MDS patients (78.1%) harbored mutations in ≥ 1 of 










1 RCMD RA 38.6 c.4138C>T p.H1380Y Nonsynonymous
2 Unclassifiable AS 32.0 c.4354C>T p.R1452X Stop gain
3 RCUD Panniculitis 44.8 c.970C>T p.Q324X Stop gain
40.0 c.4323_4323delinsTG p.A1443Cfs Frameshift insertion
4 RCUD ITP 32.5 c.1342G>T p.E448X Stop gain
29.1 c.4102T>G p.F1368V Nonsynonymous
5 RAEB Sweet syndrome 26.9 c.2685delT p.V895fs Frameshift deletion
6 RAEB None 29.4 c.4827_4828insA - Frameshift insertion
7 RAEB None 14.8 c.A5686G p.R1896G Nonsynonymous
8 RCUD None 39.5 c.C1648T p.R550X Stop gain
TET2, ten-eleven translocation 2; MDS, myelodysplastic syndrome; AID, autoimmune disease; RCMD, refractory cytopenia 
with multilineage dysplasia; RA, rheumatoid arthritis; AS, ankylosing spondylitis; RCUD, refractory cytopenia with unilin-
eage dysplasia; ITP, immune thrombocytopenia; RAEB, refractory anemia with excess blasts.
Table 2. Regression analyses for the development of autoim-
mune diseases in MDS patients
Variable
Univariate
OR (95% CI) p value
Age at MDS diagnosis 0.99 (0.96–1.03) 0.640
Sex, male 1.83 (0.59–5.72) 0.300
IPSS score 0.95 (0.52–1.74) 0.860
TET2 mutation 8.18 (1.70–39.38) 0.009
MDS, myelodysplastic syndrome; OR, odds ratio; CI, confi-
dence interval; IPSS, International Prognostic Scoring Sys-
tem; TET2, ten-eleven translocation 2.
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88 selected genes associated with hematologic malignan-
cy. Strikingly, only the TET2 mutation was enriched sig-
nificantly in patients with an AID compared with those 
without. Subgroup analysis of 43 MDS patients without 
a karyotypic abnormality revealed that three (30%) of ten 
patients with an AID harbored a TET2 mutation com-
pared with three of 33 patients (9%) without an AID (p = 
0.04) (data not shown). Therefore, alterations at the gene 
level might be critical for autoimmunity in MDS.
TET2 belongs to the TET family and plays a role in 
converting 5-methyl-cytosine (5-mC) to 5-hydroxymeth-
yl-cytosine (5-hmC) during DNA demethylation [19]. 
Accordingly, loss-of-function TET2 mutations lead to 
decreased TET2 enzymatic activity, which is associated 
with changes in methylation profiles and epigenetic 
dysregulation [19]. TET2 deletion is sufficient to initiate 
myeloid and lymphoid transformation [20]. TET2 con-
trols cytokine production by T cells in AIDs [21]. In ad-
dition, TET2 is a crucial negative transcriptional inhib-
itor of proinflammatory responses, and TET2 depletion 
contributes to accelerated atherosclerosis via increased 
inflammasome responses [22]. Accordingly, aberrant 
methylation of specific gene promoters might be asso-
ciated with development of hematopoietic malignancy 
and autoimmunity [20]. In line with this, all TET2 mu-
tations identified herein were variants of strong clinical 
significance and associated with presumably impaired 
TET2 function. However, a large prospective study is 
needed to investigate how TET2 mutation contributes to 
autoimmunity in MDS.
Previous studies report a strong association between 
TET2 mutations and aging [23,24]. Since TET2 mutations 
accumulate with age, it might be tempting to speculate 
that particular AIDs, especially those occurring later in 
life (e.g., polymyalgia rheumatic and giant cell arteritis 
[GCA]), might be, at least in part, caused by accumulat-
ing TET2 mutations [25,26]. A preliminary study revealed 
that TET2 mutation was not observed in GCA patients 
without MDS, suggesting that TET2 mutation contrib-
utes to development of AID in MDS patients but not in 
the general population (unpublished data). 
The study has several limitations. First, the number of 
enrolled patients was relatively small, which may affect 
robust statistical analysis (e.g., correction for multiple 
comparisons). Second, the temporal relationship be-
tween TET2 mutation and AIDs development in patients 
with MDS could not be investigated precisely since the 
exact time of TET2 mutation could not be determined. 
Third, AID cases diagnosed within 5 years before MDS 
diagnosis were included, since chronic smoldering cas-
es of MDS might remain undiagnosed for many years 
until emergence of obvious clinical symptoms. Howev-
er, it is possible that those cases might not be related to 
MDS. Fourth, ITP in three patients was defined as iso-
lated thrombocytopenia in the presence of antiplatelet 
antibodies after excluding other causes of thrombocyto-
penia. However, it is difficult to differentiate ITP from 
dysplastic megakaryopoiesis with a high degree of cer-
tainty. In addition, one patient with autoimmune thy-
roiditis after allogenic peripheral blood stem cell trans-
plantation was included as an MDS-related AID. Since 
hematopoietic cell transplantation might clear MDS 
clones that might induce Grave’s disease, Graves’ dis-
ease occurring after hematopoietic cell transplantation 
might not be related to MDS; rather, it could be a mani-
festation of graft versus host disease. Finally, it would be 
of particular interest to investigate whether disappear-
ance of clones with TET2 mutations after treatment of 
MDS (e.g., with BM transplantation) is associated with 
improvement of autoimmune phenomena. Further 
studies are warranted to validate the current finding in 
independent cohorts. 
In conclusion, this study is the first to show that mu-
tation of TET2 may be associated with a significant in-
crease in the risk of AID in patients with MDS. Large 
prospective and validation studies are needed to iden-
tify more precise relationships and underlying mecha-
nisms.
KEY MESSAGE
1. Autoimmunity is common in myelodysplastic 
syndrome (MDS).
2. Mutation of ten-eleven translocation 2 (TET-2), 
an epigenetic regulator, is associated signif i-
cantly with increased risk of autoimmunity in 
MDS.
3. Particular genetic alterations might contribute 
to both autoimmunity and malignancy in MDS.
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Supplementary Table 1. Genetic mutational profiles of MDS patients with or without AID
Variable AID (n = 16) No AID (n = 57) p value
Presence of genetic mutation 11 (68.8) 46 (80.7) 0.32
No. of mutated genes 0.32
0 5 (31.3) 11 (19.3)
1 3 (18.8) 13 (22.8)
2 3 (18.8) 10 (17.5)
3 1 (6.3) 12 (21.1)
4 4 (25.0) 4 (7.0)
5 0 2 (3.5)
6 0 4 (7.0)
7 0 1 (1.8)
Classifier of mutated genes
Chromatin modification
ASXL1 3 (18.8) 13 (22.9) 0.84
EZH2 1 (6.3) 4 (7.0) 1.0
Splicing 
PRPF40B 0 1 (1.8) 1.0
SF3B1 2 (12.5) 4 (7.0) 0.61
SRSF2 2 (12.5) 3 (5.3) 0.3
U2AF1 0 9 (15.8) 0.19
U2AF2 0 1 (1.8) 1.0
ZRSR2 1 (6.3) 2 (3.5) 0.53
DNA methylation 
DNMT3A 1 (6.3) 5 (8.8) 0.86
IDH2 0 3 (5.3) 1.0
TET2 5 (31.3) 3 (5.3) 0.001
Transcription 
BCOR 0 4 (7.0) 0.57
BRD4 0 1 (1.8) 1.0
CEBPA 0 3 (5.3) 1.0
EGR2 0 1 (1.8) 1.0
ETV6 0 1 (1.8) 1.0
GATA1 0 1 (1.8) 1.0
GATA2 0 1 (1.8) 1.0
IKZF1 0 1 (1.8) 1.0
NPM1 0 2 (3.5) 1.0
RUNX1 1 (6.3) 4 (7.0) 1.0
TP53 2 (12.5) 12 (21.1) 0.31
WT1 1 (6.3) 2 (3.5) 0.53
Receptor kinase
BIRC3 0 1 (1.8) 1.0
CSF3R 0 3 (5.3) 1.0
JAK2 0 3 (5.3) 1.0
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Variable AID (n = 16) No AID (n = 57) p value
MPL 0 2 (3.5) 1.0
NOTCH1 0 4 (7.0) 0.57
RAS pathway
NF1 0 2 (3.5) 1.0
NRAS 0 2 (3.5) 1.0
PTPNII 0 1 (1.8) 1.0
Signaling
PRKD3 1 (6.3) 0 0.22
SH2B3 0 1 (1.8) 1.0
Cell cycle/DNA repair
RB1 1 (6.3) 1 (1.8) 0.39
ATM 0 3 (5.3) 1.0
BARD1 0 1 (1.8) 1.0
Cohesin
SMC1A 0 1 (1.8) 1.0
SMC3 0 1 (1.8) 1.0
STAG2 1 (6.3) 3 (5.3) 1.0
Others
DIS3 0 1 (1.8) 1.0
FAT4 0 3 (5.3) 1.0
LAMB4 0 2 (3.5) 1.0
LRP1B 0 2 (1.6)
PLEKHG5 1 (6.3) 3 (5.3) 1.0
POLG 1 (6.3) 1 (1.8) 0.39
RIPKI 0 1 (1.8) 1.0
SCRIB 0 1 (1.8) 1.0
SETBP1 0 1 (1.8) 1.0
TGM7 0 1 (1.8) 1.0
Values are presented as number (%). No mutation was found 39 of 88 genes; ATRX, SF1, SF3A1, IDH1, BRD2, PHF6, TCF12, CS-
F1R, FBXW7, FLT3, KIT, BRAF, CBL, KRAS, ITPKB, MYD88, CCND1, CDKN2A, BRCC3, RAD21, CALR, CARD6, CHD2, DAP3, 
DDX3X, EEF1E1, FAM46C, HIST1H1E, KIAA0355, KLHL6, MED12, MAPK1, NFKBIE, POT1, PTEN, SAMND1, SMARCA2, XPO1, 
ZMYM3.
MDS, myelodysplastic syndrome; AID, autoimmune disease.
Supplementary Table 1. Continued
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Supplementary Figure 1. Sequencing data processing 
and variant calling process. BWA, Burrows-Wheel-
er-Aligner; SNV, single nucleotide variants; dbSNP, 
single nucleotide polymorphism database; ESP, exome 
sequencing project; COSMIC, Catalogue Of Somatic 
Mutations In Cancer.
.fastq data from HiSeq 2500
Process and align to human reference genome (hg19) using BWA
Remove duplicate reads using Picard MarkDuplicates
Eliminate low-quality data using the following criteria:
• Reads with < 10 mapping quality
• Bases with < 20 base quality
Eliminate low-quality data using the following criteria:
• Reads with < 10 mapping quality
• Variants with < 0.01 allele frequency
Remove known missense SNVs registered in the following databases:
• dbSNP
• 1,000 genome (2012/04) with ≥ 0.005 allele frequency
•  ESP 6500 with ≥ 0.005 allele frequency
•  In-jouse Korean Exome database with ≥ 0.002 allele frequency
Detect SNV and indel information
Remove synonymous SNVs
Rescue candidate mutations registered in COSMIC V60 database
Remove ambiguous missense SNVs predicted to “benign” by polyphen
